PAMEX pramipexole dihydrochloride 0.125 mg tablets blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

pramipexole dihydrochloride monohydrate, Quantity: 0.125 mg

Disponível em:

Arrotex Pharmaceuticals Pty Ltd

DCI (Denominação Comum Internacional):

pramipexole dihydrochloride monohydrate

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: silicon dioxide; pregelatinised maize starch; povidone; mannitol; magnesium stearate

Via de administração:

Oral

Unidades em pacote:

10, 30, 100

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary Restless Legs Syndrome.

Resumo do produto:

Visual Identification: White, circular, flat, beveled edged uncoated tablets debossed with 'CL' on one side and '2' on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status de autorização:

Licence status A

Data de autorização:

2014-09-23